EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Charles E Geyer, Michael Untch, Chiun-Sheng Huang, Max S Mano, Eleftherios P Mamounas, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo, Hans H Fischer, Véronique D'Hondt, Alison K Conlin und 23 weitere

New England Journal of Medicine · 16.01.2025 · 392 (3) · 249-257

DOI: 10.1056/nejmoa2406070 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 16.01.2025. Verfasst von Charles E Geyer und 34 weiteren Autor:innen. Beteiligte Einrichtung: From the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation (C.E.G., E.P.M., N.W., P.R., I.L.W., A.M.B.) and University of Pittsb…. Hauptthemen laut MEDLINE: Ado-Trastuzumab Emtansine, Antineoplastic Agents, Immunological, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 168-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ado-Trastuzumab EmtansineAntineoplastic Agents, ImmunologicalBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesTrastuzumabAdultAgedFemaleHumansMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFollow-Up StudiesKaplan-Meier EstimateNeoadjuvant TherapyNeoplasm, ResidualNeoplasm InvasivenessMastectomyNeoplasm Recurrence, LocalTreatment Outcome

Substanzen

Ado-Trastuzumab EmtansineAntineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, human

Autor:innen und Institutionen

  • From the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation (C.E.G., E.P.M., N.W., P.R., I.L.W., A.M.B.) and University of Pittsburgh School of Medicine-UPMC Hillman Cancer Center (C.E.G., N.W., P.R.…

Förderung

  • Genentech

Zitieren

APA

Geyer, C. E., Untch, M., Huang, C. S., Mano, M. S., Mamounas, E. P., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., Fischer, H. H., D'Hondt, V., Conlin, A. K., Guarneri, V., Wapnir, I. L., Jackisch, C., Arce-Salinas, C., Fasching, P. A., DiGiovanna, M. P., Crown, J. P., …, & KATHERINE Study Group (2025). Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. New England Journal of Medicine, 392(3), 249-257. https://doi.org/10.1056/nejmoa2406070

Vancouver

Geyer CE, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, et al. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. New England Journal of Medicine. 2025;392(3):249-257. doi:10.1056/nejmoa2406070

BibTeX
@article{Geyer2025,
  author = {Geyer, Charles E and Untch, Michael and Huang, Chiun-Sheng and Mano, Max S and Mamounas, Eleftherios P and Wolmark, Norman and Rastogi, Priya and Schneeweiss, Andreas and Redondo, Andres and Fischer, Hans H and D'Hondt, Véronique and Conlin, Alison K and Guarneri, Valentina and Wapnir, Irene L and Jackisch, Christian and Arce-Salinas, Claudia and Fasching, Peter A and DiGiovanna, Michael P and Crown, John P and Wuelfing, Pia and Shao, Zhimin and Rota Caremoli, Elena and Bonnefoi, Hervé R and Hennessy, Bryan T and Stamatovic, Ljiljana and Castro-Salguero, Hugo and Brufsky, Adam M and Knott, Adam and Siddiqui, Asna and Lambertini, Chiara and Boulet, Thomas and Nyawira, Beatrice and Restuccia, Eleonora and Loibl, Sibylle and KATHERINE Study Group, KATHERINE Study Group},
  title = {Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {3},
  pages = {249--257},
  doi = {10.1056/nejmoa2406070}
}
Kostenlos starten →